Longboard Pharmaceuticals, Inc.
longboardpharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 7, 2024. Its latest SEC filing is a SCHEDULE 13G/A from Feb 14, 2025.
10-Q for Q3 FY2024, filed Nov 7, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops experimental medicines for neurological diseases, including epilepsy and rare neuroinflammatory conditions.
10-K for FY2023, filed Mar 12, 2024We are a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. We were…View ↗
We are developing bexicaserin, an oral, centrally acting, 5-HT2C superagonist for DEEs and other epileptic disorders. Bexicaserin is the…View ↗
We are developing LP659, a centrally acting, S1P1,5 receptor modulator for rare neuroinflammatory conditions with high unmet medical need.…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2023, filed Mar 12, 2024
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 7, 2024
−$24.5MView ↗
- ▲ +90% (Loss)
- vs −$12.9M in Q3 FY2023
-
Dec 2, 2024
Lundbeck completed its acquisition of Longboard.
Longboard became an indirect wholly owned subsidiary of Lundbeck’s parent after the merger.
Sources
8-K, filed Dec 2, 2024
The Offer expired at one minute following 11:59 p.m., Eastern Time, on November 27, 2024 (the “Expiration Time”) and was not extended.…View ↗
-
Oct 15, 2024
Longboard agreed to be acquired by Lundbeck.
The agreement provided for a cash tender offer for all Longboard shares, followed by a merger.
Sources
8-K, filed Oct 15, 2024
On October 14, 2024, Longboard Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Longboard”), entered into an Agreement and…View ↗
Who Did They Compete With?
Competes with Jazz, UCB, SK Life Sciences, Marinus Pharmaceuticals, and Biocodex
10-K for FY2023, filed Mar 12, 2024DEEs are commonly treated with multiple combinations of ASMs though physician preference for administered therapies differs across…View ↗
Loading...
